×
About 9,450 results

ALLMedicine™ Leukemias Center

Research & Reviews  4,473 results

Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI r...
https://doi.org/10.1158/1078-0432.CCR-20-3679
Clinical Cancer Research : an Official Journal of the Ame... Makela E, Pavic K et. al.

Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...

Benzene Exposure and Cancer Risk from Commercial Gasoline Station Fueling Events Using ...
https://doi.org/10.3390/ijerph18041872
International Journal of Environmental Research and Publi... Patton AN, Levy-Zamora M et. al.

Mar 6th, 2021 - Tens of millions of individuals go to gasoline stations on a daily basis in the United States. One of the constituents of gasoline is benzene, a Group 1 carcinogen that has been strongly linked to both occupational and non-occupational leukemias. ...

RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/runx1/

Mar 3rd, 2021 - RUNX1 familial platelet disorder with associated myeloid malignancies (RUNX1-FPDMM) is characterized by prolonged bleeding and/or easy bruising and an increased risk of developing a hematologic malignancy. RUNX1-FPDMM is characterized by thrombocy...

EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
https://doi.org/10.1182/blood.2020009564
Blood Somasundaram R, Jensen CT et. al.

Feb 23rd, 2021 - Genes encoding B lineage restricted transcription factors are frequently mutated in B-lymphoid leukemias, suggesting a close link between normal and malignant B-cell development. One of these transcription factors is Early B cell Factor 1 (EBF1), ...

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886212
PloS One; Mosquera Orgueira A, Peleteiro Raíndo A et. al.

Feb 16th, 2021 - FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously...

see more →

Guidelines  19 results

Acute Myeloid Leukemia - AML | ARUPConsult Lab Test Selection
https://arupconsult.com/content/acute-myeloid-leukemia

Jun 30th, 2019 - Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in im...

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/6/article-p721.xml
Journal of the National Comprehensive Cancer Network;

Jun 14th, 2019 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for ...

23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
https://www.gotoper.com/conferences/hem/meetings/23rd-international-congress-on-hematologic-malignancies-focus-on-leukemias-lymphomas-and-myeloma

Feb 27th, 2019 - Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the bes...

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

see more →

Drugs  39 results see all →

Clinicaltrials.gov  4,673 results

Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI r...
https://doi.org/10.1158/1078-0432.CCR-20-3679
Clinical Cancer Research : an Official Journal of the Ame... Makela E, Pavic K et. al.

Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...

Benzene Exposure and Cancer Risk from Commercial Gasoline Station Fueling Events Using ...
https://doi.org/10.3390/ijerph18041872
International Journal of Environmental Research and Publi... Patton AN, Levy-Zamora M et. al.

Mar 6th, 2021 - Tens of millions of individuals go to gasoline stations on a daily basis in the United States. One of the constituents of gasoline is benzene, a Group 1 carcinogen that has been strongly linked to both occupational and non-occupational leukemias. ...

RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/runx1/

Mar 3rd, 2021 - RUNX1 familial platelet disorder with associated myeloid malignancies (RUNX1-FPDMM) is characterized by prolonged bleeding and/or easy bruising and an increased risk of developing a hematologic malignancy. RUNX1-FPDMM is characterized by thrombocy...

EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
https://doi.org/10.1182/blood.2020009564
Blood Somasundaram R, Jensen CT et. al.

Feb 23rd, 2021 - Genes encoding B lineage restricted transcription factors are frequently mutated in B-lymphoid leukemias, suggesting a close link between normal and malignant B-cell development. One of these transcription factors is Early B cell Factor 1 (EBF1), ...

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886212
PloS One; Mosquera Orgueira A, Peleteiro Raíndo A et. al.

Feb 16th, 2021 - FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously...

see more →

News  245 results

The Next 'Big Thing' for Blood Cancers Featured at ASH 2019
https://www.staging.medscape.com/viewarticle/921942

Dec 6th, 2019 - The prospect of an "off-the-shelf" product, rather than one that needs to be grown individually for each patient, is a "very exciting" proposition, say experts discussing new data that will be presented at the forthcoming American Society of Hemat...

The Next 'Big Thing' for Blood Cancers Featured at ASH 2019
https://www.medscape.com/viewarticle/921942

Dec 6th, 2019 - The prospect of an "off-the-shelf" product, rather than one that needs to be grown individually for each patient, is a "very exciting" proposition, say experts discussing new data that will be presented at the forthcoming American Society of Hemat...

Federal Health Care Cancer Data Trends 2019
https://www.mdedge.com/fedprac/article/209596/federal-health-care-cancer-data-trends-2019?channel=167

Oct 7th, 2019 - Click here to access Federal Health Care Cancer Data Trends 2019 Table of Contents Introduction Cancer in the VA: The Big Picture Hepatocellular Carcinoma Prostate Cancer Multiple Myeloma Lung Cancer in the VA at a National Level Lung Cancer – Reg.

Leukemia Federal Health Care Data Trends
https://www.mdedge.com/fedprac/avaho/article/208837/oncology/leukemia-federal-health-care-data-trends?channel=263
Joao L. Ascensao, MD, PhD, FACP

Sep 25th, 2019 - (function(n){var r="_ion_ionizer",t=n. getElementsByTagName("script"),i;t=t[t.

see more →

Patient Education  1 results see all →